Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts

Transplantation

Volumn 66, Issue 11, 1998, Pages 1439-1450

  Ierino, Francesco L ^a   Kozlowski, Tomek ^a   Siegel, Jonathan B ^b   Shimizu, Akira ^a   Colvin, Robert B ^a   Banerjee, Papia T ^c   Cooper, David K C ^a   Cosimi, A Benedict ^a   Bach, Fritz H ^b   Sachs, David H ^a   Robson, Simon C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BioTransplant Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3D; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BABOON; BLEEDING TENDENCY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; SPECIES DIFFERENCE; THROMBOCYTOPENIA;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; GRAFT REJECTION; KIDNEY; KIDNEY TRANSPLANTATION; MICROSCOPY, ELECTRON; PAPIO; SWINE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032535196     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812150-00006     Document Type: Article

References (60)

1. Bach PH, Robson SC, Ferran C, et al. Endothelial cell activation and thromboregulation during xenograft rejection [Review], Immunol Rev. 1994; 141 (5): 5.
2. Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection [Review]. Immunol Today 1996; 17 (8): 379.
3. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52 (2): 214.
4. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140 (5): 1157.
5. Dalmasso AP, Platt JL, Bach FH. Reaction of complement with endothelial cells in a model of xenotransplantation. Clin Exp Immunol 1991; 1: 31.
6. Robson SC, Siegel JB, Lesnikoski BA, et al. Aggregation of human platelets induced by porcine endothelial cells is dependent upon both activation of complement and thrombin generation. Xenotransplantation 1996; 3: 24.
7. Platt JL. Xenotransplantation: recent progress and current perspectives [Review]. Curr Opin Immunol 1996; 8 (5): 721.
8. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807.
9. Levi M, Vanderpoll T, Tencate H, Vandeventer S. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia [Review]. Eur J Clin Invest 1997; 27: 3.
10. Peerschke EIB, Reid KBM, Ghebrehiwet B. Platelet activation by C1q results in the induction of all/bill integrins and the expression of P-selectin and procoagulant activity. J Exp Med 1993; 178: 579.
11. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992; 29 (170): 170.
12. Robson SC, Kaczmarek E, Siegel JB, et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153.
13. Jurd KM, Gibbs RV, Hunt BJ. Activation of human prothrombin by porcine aortic endothelial cells: a potential barrier to pig to human xenotransplantation. Blood Coag Fibrinolysis 1996; 7: 336.
14. Bach FH, Robson SC, Winkler H, et al. Endothelial cell activation and other barriers to xenotransplantation. Nat Med. 1995; 1: 869.
15. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decayaccelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530.
16. Kopp CW, Siegel JB, Hancock WW, et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749.
17. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; in press.
18. Lawson JH, Platt JL. Molecular barriers to xenotransplantation. Transplantation 1996; 62: 303.
19. Schulte am Esch J, Siegel JB, Cruz M, Robson SC. The A1 domain of von Willebrand factor expressed on cell membranes directly activates platelets. Blood 1997; 90: 4425.
20. Sachs DH. MHC homozygous miniature swine. In: Swindle MM, Moody DC, Phillips LD, eds. Swine as models in biomedical research. Ames, LA: Iowa State University Press, 1992: 3.
21. Sachs DH, Leight G, Cone J, Schwartz S, Stuart L, Rosenberg S. Transplantation in miniature swine. I. Fixation of the major histocompatibility complex. Transplantation 1976; 22: 559.
22. Sablinski T, Gianello PR, Bailin M, et al. Pig to monkey bone marrow and kidney xenotransplantation. Surgery 1997; 121: 381.
23. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322.
24. Candinas DR, Lesnikoski BA, Hancock WW, et al. Inhibition of platelet GPIIbIIIa receptors prolongs discordant xenograft survival. Transplantation 1996; 62: 1.
25. Lawson JH, Daniels LJ, Platt JL. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc 1997; 29: 884.
26. Bach FH, Robson SC, Ferran C, et al. Xenotransplantation: endothelial cell activation and beyond. Transplant Proc 1995; 27: 77.
27. Koyamada N, Miyatake T, Candinas D, et al. Apyrase administration prolongs discordant xenograft survival. Transplantation 1996; 62 (12): 1739.
28. Candinas D, Lesnikoski BA, Koyamada N, et al. Inhibition of platelet GPIIbIIIa prolongs discordant xenograft survival. Transplantation 1996; 62: 1.
29. Robson SC, Young VK, Cook NS, et al. Thrombin inhibition in an ex vivo model of hyperacute xenograft rejection. Transplantation 1996; 61: 862.
30. Pruitt SK, Bollinger RR, Collins BH, et al. Continuous complement (c) inhibition using soluble complement receptor type 1 (SCR-1): effect on hyperacute rejection (HAR) of pig-to-primate cardiac xenografts. Transplant Proc 1996; 28: 2.
31. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809.
32. Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system [Review]. Immunol Today 1991; 12: 338.
33. Vannucchi AM, Rafanelli D, Longo G, et al. Early hemostatic alterations following bone marrow transplantation: a prospective study. Haematologica 1994; 79: 519.
34. Wassmann B, Martin H, Elsner S, et al. Microangiopathic hemolytic anemia and renal impairment following autologous bone marrow transplantation: a case of hemolytic uremic syndrome. Bone Marrow Transplant 1994; 14 (5): 849.
35. Gharpure VS, Devine SM, Holland HK, Geller RB, Otoole K, Wingard JR. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 715.
36. Knobl P, Rintelen C, Kornek G, et al. Plasma exchange for treatment of thrombotic thrombocytopenic purpura in critically ill patients. Intensive Care Med 1997; 23: 44.
37. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256.
38. Bartholomew AM, Cosimi AB, Sachs DH, et al. A study of tolerance in a concordant xenograft model. Transplant Proc 1997; 29: 923.
39. Rosenberg JC, Broersma RJ, Bullemer G, Mammen EF, Lenaghan R, Rosenberg BF. Relationship of platelets, blood coagulation, and fibrinolysis to hyperacute rejection of renal xenografts. Transplantation 1969; 8: 152.
40. Broersma RJ, Bullemer GD, Rosenberg JC, Lenaghan R, Rosenberg BF, Mammen EF. Coagulation changes in hyperacute rejection of renal xenografts. Thromb Diathesis Haemorrhag Suppl 1969; 36: 333.
41. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
42. Artrip JH, Itescu S, Minanov OP, Kwiatkowski PA, Michler RE. Cardiac xenotransplantation. Curr Opin Cardiol 1997; 12: 172.
43. Davis EA, Jakobs F, Pruitt SK, et al. Overcoming rejection in pig-to-primate cardiac xenotransplantation. Transplant Proc 1997; 29: 938.
44. Davis EA, Pruitt SK, Greene PS, et al. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation 1996; 62: 1018.
45. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96: 2404.
46. Pruitt SK, Bollinger RR, Collins BH, et al. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997; 63: 900.
47. Kobayashi T, Neethling FA, Taniguchi S, et al. Investigation of the anti-complement agents, fut-175 and k76cooh, in discordant xenotransplantation. Xenotransplantation 1996; 3: 237.
48. Byrne G, McCurry KR, Martin MJ, Mcclellan SM, Platt JL, Logan JS. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149.
49. Diamond LE, McCurry KR, Martin MJ, et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996; 61: 124.
50. White DJG. hDAF transgenic pig organs: are they concordant for human transplantation. Xeno 1996; 4: 50.
51. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science 1996; 272: 689.
52. Starzl TE, Lerner RA, Dixon FJ, Groth CG, Brettschneider L, Terasaki PI. Shwartzman reaction after human renal homotransplantation. N Engl J Med 1968; 278: 642.
53. Starzl TE, Boehmig HJ, Amemiya H, et al. Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection. N Engl J Med 1970; 283: 383.
54. Breimer ME, Bjorck S, Svalander CT, et al. Extracorporeal (ex vivo) connection of pig kidneys to humans. I. Clinical data and studies of platelet destruction. Xenotransplantation 1996; 3: 328.
55. Chari RS, Collins BH, Magee JC. Brief report - Treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med 1994; 331: 234.
56. Makowka L, Cramer DV, Hoffman A, Sher L, Podesta L. Pig liver grafts as a temporary bridge for human allografting. Xeno 1993; 1: 27.
57. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745.
58. Vandammieras M, Muller AD, Vanhinsbergh V, Mullers W, Bomans P, Bruggeman CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992; 68: 364.
59. Etingin OR, Silverstein RL, Hajjar DP. Identification of a monocyte receptor on herpesvirus-infected endothelial cells. Proc Natl Acad Sci USA 1991; 88: 7200.
60. Chalifoux LV, Simon MA, Pauley DR, MacKey JJ, Wyand MS, Ringler DJ. Arteriopathy in macaques infected with simian immunodeficiency virus. Lab Invest 1992; 67: 338.